PDF(Pubmed)
Abstract：
OBJECTIVE: This study aimed to evaluate the effectiveness of somatostatin analogues (SA) for cystoid maculopathy (CM) in retinitis pigmentosa (RP) patients.
METHODS: In this retrospective case series, clinical and imaging characteristics of 28 RP patients with CM, unresponsive to carbonic anhydrase inhibitors, were collected from medical charts. All patients received SA treatment as an alternative (octreotide long-acting release at 20 mg/month or 30 mg/month, or lanreotide at 90 mg/month or 120 mg/month). Outcome measures were mean reduction in foveal thickness (FT) and foveal volume (FV) and mean increase in best-corrected visual acuity at 3, 6 and 12 months of treatment initiation. Linear mixed models were used to calculate the effectiveness over time.
RESULTS: 52 eyes of 28 RP patients were included; 39% were male. The median age at the start of treatment was 39 years (IQR 30-53). Median follow-up was 12 months (range 6-12). From baseline to 12 months, the mean FT decreased from 409±136 µm to 334±119 µm and the mean FV decreased from 0.31±0.10 mm3 to 0.25±0.04 mm3. Linear mixed model analyses showed a significant decrease in log FT and log FV at 3, 6 and 12 months after the start of treatment compared with baseline measurements (p<0.001, p<0.001, p<0.001). Mean best-corrected visual acuity did not increase significantly (0.46±0.35 logMAR to 0.45±0.38 logMAR after 12 months).
CONCLUSIONS: SA may be an effective alternative treatment to reduce CM in RP patients.
METHODS: In this retrospective case series, clinical and imaging characteristics of 28 RP patients with CM, unresponsive to carbonic anhydrase inhibitors, were collected from medical charts. All patients received SA treatment as an alternative (octreotide long-acting release at 20 mg/month or 30 mg/month, or lanreotide at 90 mg/month or 120 mg/month). Outcome measures were mean reduction in foveal thickness (FT) and foveal volume (FV) and mean increase in best-corrected visual acuity at 3, 6 and 12 months of treatment initiation. Linear mixed models were used to calculate the effectiveness over time.
RESULTS: 52 eyes of 28 RP patients were included; 39% were male. The median age at the start of treatment was 39 years (IQR 30-53). Median follow-up was 12 months (range 6-12). From baseline to 12 months, the mean FT decreased from 409±136 µm to 334±119 µm and the mean FV decreased from 0.31±0.10 mm3 to 0.25±0.04 mm3. Linear mixed model analyses showed a significant decrease in log FT and log FV at 3, 6 and 12 months after the start of treatment compared with baseline measurements (p<0.001, p<0.001, p<0.001). Mean best-corrected visual acuity did not increase significantly (0.46±0.35 logMAR to 0.45±0.38 logMAR after 12 months).
CONCLUSIONS: SA may be an effective alternative treatment to reduce CM in RP patients.
摘要：
目的：本研究旨在评估生长抑素类似物（SA）治疗色素性视网膜炎（RP）患者囊样黄斑病变（CM）的有效性。
方法：在本回顾性病例系列中，28例RP伴CM患者的临床及影像学特点,对碳酸酐酶抑制剂无反应，是从医学图表中收集的。所有患者均接受SA治疗（奥曲肽长效释放剂20mg/月或30mg/月，或兰利肽，剂量为90毫克/月或120毫克/月）。结果指标是在治疗开始的3、6和12个月时，中央凹厚度（FT）和中央凹体积（FV）的平均减少以及最佳矫正视力的平均增加。线性混合模型用于计算随时间的有效性。
结果：包括28例RP患者的52只眼；39％为男性。治疗开始时的中位年龄为39岁（IQR30-53）。中位随访时间为12个月（6-12）。从基线到12个月，平均FT从409±136µm下降到334±119µm，平均FV从0.31±0.10mm3下降到0.25±0.04mm3。线性混合模型分析显示，与基线测量相比，治疗开始后3、6和12个月的logFT和logFV显着降低（p<0.001，p<0.001，p<0.001）。平均最佳矫正视力没有显着增加（12个月后0.46±0.35logMAR至0.45±0.38logMAR）。
结论：SA可能是降低RP患者CM的有效替代治疗方法。
方法：在本回顾性病例系列中，28例RP伴CM患者的临床及影像学特点,对碳酸酐酶抑制剂无反应，是从医学图表中收集的。所有患者均接受SA治疗（奥曲肽长效释放剂20mg/月或30mg/月，或兰利肽，剂量为90毫克/月或120毫克/月）。结果指标是在治疗开始的3、6和12个月时，中央凹厚度（FT）和中央凹体积（FV）的平均减少以及最佳矫正视力的平均增加。线性混合模型用于计算随时间的有效性。
结果：包括28例RP患者的52只眼；39％为男性。治疗开始时的中位年龄为39岁（IQR30-53）。中位随访时间为12个月（6-12）。从基线到12个月，平均FT从409±136µm下降到334±119µm，平均FV从0.31±0.10mm3下降到0.25±0.04mm3。线性混合模型分析显示，与基线测量相比，治疗开始后3、6和12个月的logFT和logFV显着降低（p<0.001，p<0.001，p<0.001）。平均最佳矫正视力没有显着增加（12个月后0.46±0.35logMAR至0.45±0.38logMAR）。
结论：SA可能是降低RP患者CM的有效替代治疗方法。
